Abstract:Nucleotide-binding domain, leucine-rich-repeat-containing family, pyrin domain-containing 3 (NLRP3) is a cytosolic protein that nucleates assembly of inflammasome signaling platforms, which facilitate caspase-1-mediated IL-1β release and other inflammatory responses in myeloid leukocytes. NLRP3 inflammasomes are assembled in response to multiple pathogen- or environmental stress-induced changes in basic cell physiology, including the destabilization of lysosome integrity and activation of K(+)-permeable channels/transporters in the plasma membrane (PM). However, the quantitative relationships between lysosome membrane permeabilization (LMP), induction of increased PM K(+) permeability, and activation of NLRP3 signaling are incompletely characterized. We used Leu-Leu-O-methyl ester (LLME), a soluble lysosomotropic agent, to quantitatively track the kinetics and extent of LMP in relation to NLRP3 inflammasome signaling responses (ASC oligomerization, caspase-1 activation, IL-1β release) and PM cation fluxes in murine bone marrow-derived dendritic cells (BMDCs). Treatment of BMDCs with submillimolar (≤1 mM) LLME induced slower and partial increases in LMP that correlated with robust NLRP3 inflammasome activation and K(+) efflux. In contrast, supramillimolar (≥2 mM) LLME elicited extremely rapid and complete collapse of lysosome integrity that was correlated with suppression of inflammasome signaling. Supramillimolar LLME also induced dominant negative effects on inflammasome activation by the canonical NLRP3 agonist nigericin; this inhibition correlated with an increase in NLRP3 ubiquitination. LMP elicited rapid BMDC death by both inflammasome-dependent pyroptosis and inflammasome-independent necrosis. LMP also triggered Ca(2+) influx, which attenuated LLME-stimulated NLRP3 inflammasome signaling but potentiated LLME-induced necrosis. Taken together, these studies reveal a previously unappreciated signaling network that defines the coupling between LMP, changes in PM cation fluxes, cell death, and NLRP3 inflammasome activation.

Scaffolding of NLRP3 on osmotically swollen vesicles but not intermediate filaments promotes inflammasome assembly

NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation

Initiation and perpetuation of NLRP3 inflammasome activation and assembly

Structural basis for the oligomerization-facilitated NLRP3 activation

How location and cellular signaling combine to activate the NLRP3 inflammasome

Distinct changes in endosomal composition promote NLRP3 inflammasome activation

NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K+ efflux and Ca2+ influx

Right place, right time: localisation and assembly of the NLRP3 inflammasome

LRRC8A is essential for hypotonicity-, but not for DAMP-induced NLRP3 inflammasome activation

Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation

The NLRP3 inflammasome: activation and regulation

Disruptions in endocytic traffic contribute to the activation of the NLRP3 inflammasome

Protein kinase D at the Golgi controls NLRP3 inflammasome activation

Formation of the NLRP3 inflammasome inhibits stress granule assembly by multiple mechanisms

Hexokinase dissociation from mitochondria promotes oligomerization of VDAC that facilitates NLRP3 inflammasome assembly and activation

Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation

NLRP3, NLRP6, and NLRP12 are inflammasomes with distinct expression patterns

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

Human NLRP3 inflammasome activation leads to formation of condensate at the microtubule organizing center

Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane trafficking and inflammasome activation